We studied the effects of a long-acting analogue of somatostatin (SMS 201-995, Sandoz) in 25 patients with histologically proved metastatic carcinoid tumors and the carcinoid syndrome. This drug was self-administered by subcutaneous injection at a dose of 150 micrograms three times daily. Flushing and diarrhea associated with the syndrome were promptly relieved in 22 patients. All 25 patients had an elevated 24-hour urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA) (mean, 265 mg per 24 hours; range, 14 to 1079), which served as an objective indicator of disease activity. Eighteen of the 25 patients (72 percent) had a decrease of 50 percent or more in their urinary 5-HIAA levels, as compared with the pretreatment values. The median duration of this biochemical response was more than 12 months (range, 1 to greater than 18). Since no serious toxicity was observed, we conclude that SMS 201-995 may be appropriate for use as early therapy in patients with symptoms due to the carcinoid syndrome who have not responded to simpler measures.
This article has been cited by other articles:
Martenson, J. A., Halyard, M. Y., Sloan, J. A., Proulx, G. M., Miller, R. C., Deming, R. L., Dick, S. J., Johnson, H. A., Tai, T.H. P., Zhu, A. W., Keit, J., Stien, K. J., Atherton, P. J.
(2008). Phase III, Double-Blind Study of Depot Octreotide Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy: Results of North Central Cancer Treatment Group N00CA. JCO
26: 5248-5253
[Abstract][Full Text]
Kvols, L. K.
(2008). Revisiting C.G. Moertel's Land of Small Tumors. JCO
26: 5005-5007
[Full Text]
Castillo, J. G., Filsoufi, F., Adams, D. H., Raikhelkar, J., Zaku, B., Fischer, G. W.
(2008). Management of patients undergoing multivalvular surgery for carcinoid heart disease: the role of the anaesthetist. Br J Anaesth
101: 618-626
[Abstract][Full Text]
Grozinsky-Glasberg, S., Shimon, I., Korbonits, M., Grossman, A. B
(2008). Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer
15: 701-720
[Abstract][Full Text]
van Iersel, L. B. J., Hoekman, E. J., Gelderblom, H., Vahrmeijer, A. L., van Persijn van Meerten, E. L., Tijl, F. G. J., Hartgrink, H. H., Kuppen, P. J. K., Nortier, J. W. R., Tollenaar, R. A. E. M., van de Velde, C. J. H.
(2008). Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases. Ann. Surg. Oncol.
15: 1891-1898
[Abstract][Full Text]
Majeed, F., Porter, T. R., Tarantolo, S., Duhachek-Stapelman, A., Xie, F., Elhendy, A.
(2007). Carcinoid crisis and reversible right ventricular dysfunction after embolization in untreated carcinoid syndrome. Eur J Echocardiogr
8: 386-389
[Abstract][Full Text]
Kovacs, S. P., Promisloff, R.
(2007). CARCINOID TUMORLETS: A RARE CONDITION THAT CAN PRESENT WITH A COMMON SYMPTOM. Chest
132: 706b-707
[Abstract]
Kulke, M. H
(2007). Gastrointestinal neuroendocrine tumors: a role for targeted therapies?. Endocr Relat Cancer
14: 207-219
[Abstract][Full Text]
Moller, J. E., Pellikka, P. A., Bernheim, A. M., Schaff, H. V., Rubin, J., Connolly, H. M.
(2005). Prognosis of Carcinoid Heart Disease: Analysis of 200 Cases Over Two Decades. Circulation
112: 3320-3327
[Abstract][Full Text]
Seboek, D., Linscheid, P., Zulewski, H., Langer, I., Christ-Crain, M., Keller, U., Muller, B.
(2004). Somatostatin Is Expressed and Secreted by Human Adipose Tissue upon Infection and Inflammation. J. Clin. Endocrinol. Metab.
89: 4833-4839
[Abstract][Full Text]
Kaltsas, G. A., Besser, G. M., Grossman, A. B.
(2004). The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors. Endocr. Rev.
25: 458-511
[Abstract][Full Text]
Cardillo, G., Sera, F., Di Martino, M., Graziano, P., Giunti, R., Carbone, L., Facciolo, F., Martelli, M.
(2004). Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann. Thorac. Surg.
77: 1781-1785
[Abstract][Full Text]
Dalm, V. A.S.H., Hofland, L. J., Mooy, C. M., Waaijers, M. A., van Koetsveld, P. M., Langerak, A. W., Staal, F. T.J., van der Lely, A.-J., Lamberts, S. W.J., van Hagen, M. P.
(2004). Somatostatin Receptors in Malignant Lymphomas: Targets for Radiotherapy?. JNM
45: 8-16
[Abstract][Full Text]
Chada, S. C., Punnam, S., Punnam, A.
(2003). Vocal Cord and Tracheal Carcinoid Tumor. Chest
124: 308S-309
[Abstract][Full Text]
Faiss, S., Pape, U.-F., Bohmig, M., Dorffel, Y., Mansmann, U., Golder, W., Riecken, E. O., Wiedenmann, B.
(2003). Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors--The International Lanreotide and Interferon Alfa Study Group. JCO
21: 2689-2696
[Abstract][Full Text]
Loewe, C., Schindl, M., Cejna, M., Niederle, B., Lammer, J., Thurnher, S.
(2003). Permanent Transarterial Embolization of Neuroendocrine Metastases of the Liver Using Cyanoacrylate and Lipiodol: Assessment of Mid- and Long-Term Results. Am. J. Roentgenol.
180: 1379-1384
[Abstract][Full Text]
Moller, J. E., Connolly, H. M., Rubin, J., Seward, J. B., Modesto, K., Pellikka, P. A.
(2003). Factors Associated with Progression of Carcinoid Heart Disease. NEJM
348: 1005-1015
[Abstract][Full Text]
Hofland, L. J., Lamberts, S. W. J.
(2003). The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance. Endocr. Rev.
24: 28-47
[Abstract][Full Text]
Meijer, W. G., van der Veer, E., Jager, P. L., van der Jagt, E. J., Piers, B. A., Kema, I. P., de Vries, E. G.E., Willemse, P. H.B.
(2003). Bone Metastases in Carcinoid Tumors: Clinical Features, Imaging Characteristics, and Markers of Bone Metabolism. JNM
44: 184-191
[Abstract][Full Text]
Slooter, G. D., Aalbers, A. G.J., Breeman, W. A.P., Hiemstra, C. A., Marquet, R. L., Krenning, E. P., van Eijck, C. H.J.
(2002). The Inhibitory Effect of 111In-DTPA0-Octreotide on Intrahepatic Tumor Growth After Partial Hepatectomy. JNM
43: 1681-1687
[Abstract][Full Text]
Craig, C E H, Gallen, I W
(2002). Possible functional regression of insulinoma with prolonged octreotide. Postgrad. Med. J.
78: 623-624
[Abstract][Full Text]
Connolly, H. M., Schaff, H. V., Mullany, C. J., Abel, M. D., Pellikka, P. A.
(2002). Carcinoid Heart Disease: Impact of Pulmonary Valve Replacement in Right Ventricular Function and Remodeling. Circulation
106: I-51-I-56
[Abstract][Full Text]
Hejna, M., Schmidinger, M., Raderer, M.
(2002). The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?. Ann Oncol
13: 653-668
[Abstract][Full Text]
Waldherr, C., Pless, M., Maecke, H. R., Schumacher, T., Crazzolara, A., Nitzsche, E. U., Haldemann, A., Mueller-Brand, J.
(2002). Tumor Response and Clinical Benefit in Neuroendocrine Tumors After 7.4 GBq 90Y-DOTATOC. JNM
43: 610-616
[Abstract][Full Text]
Connolly, H. M., Schaff, H. V., Mullany, C. J., Rubin, J., Abel, M. D., Pellikka, P. A.
(2001). Surgical Management of Left-Sided Carcinoid Heart Disease. Circulation
104: I-36-40
[Abstract][Full Text]
Hoegerle, S., Altehoefer, C., Ghanem, N., Koehler, G., Waller, C. F., Scheruebl, H., Moser, E., Nitzsche, E.
(2001). Whole-Body 18F Dopa PET for Detection of Gastrolintestinal Carcinoid Tumors. Radiology
220: 373-380
[Abstract][Full Text]
Fink, G., Krelbaum, T., Yellin, A., Bendayan, D., Saute, M., Glazer, M., Kramer, M. R.
(2001). Pulmonary Carcinoid : Presentation, Diagnosis, and Outcome in 142 Cases in Israel and Review of 640 Cases From the Literature. Chest
119: 1647-1651
[Abstract][Full Text]
Kwekkeboom, D., Krenning, E. P., de Jong, M.
(2000). Peptide Receptor Imaging and Therapy. JNM
41: 1704-1713
[Abstract][Full Text]
Schulz, S., Pauli, S. U., Schulz, S., Händel, M., Dietzmann, K., Firsching, R., Höllt, V.
(2000). Immunohistochemical Determination of Five Somatostatin Receptors in Meningioma Reveals Frequent Overexpression of Somatostatin Receptor Subtype sst2A. Clin. Cancer Res.
6: 1865-1874
[Abstract][Full Text]
Wymenga, A.N.M., Eriksson, B., Salmela, P.I., Jacobsen, M.B., Van Cutsem, E.J.D.G., Fiasse, R.H., Valimaki, M.J., Renstrup, J., de Vries, E.G.E., Oberg, K.E.
(1999). Efficacy and Safety of Prolonged-Release Lanreotide in Patients With Gastrointestinal Neuroendocrine Tumors and Hormone-Related Symptoms. JCO
17: 1111-1111
[Abstract][Full Text]
Kulke, M. H., Mayer, R. J.
(1999). Carcinoid Tumors. NEJM
340: 858-868
[Full Text]
Rubin, J., Ajani, J., Schirmer, W., Venook, A. P., Bukowski, R., Pommier, R., Saltz, L., Dandona, P., Anthony, L.
(1999). Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome. JCO
17: 600-600
[Abstract][Full Text]
Öberg, K.
(1998). Carcinoid Tumors: Current Concepts in Diagnosis and Treatment. The Oncologist
3: 339-345
[Abstract][Full Text]
Saslow, S B, Scolapio, J S, Camilleri, M, Forstrom, L A, Thomforde, G M, Burton, D D, Rubin, J, Pitot, H C, Zinsmeister, A R
(1998). Medium term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea. Gut
42: 628-634
[Abstract][Full Text]
Lamberts, S. W.J., van der Lely, A.-J., de Herder, W. W., Hofland, L. J.
(1996). Octreotide. NEJM
334: 246-254
[Full Text]
Previous
